KPV vs Larazotide
Two gut peptides at opposite ends of the pipeline: KPV has never been tried in humans, larazotide was tried in celiac disease and its pivotal Phase 3 failed.
Short answer
Larazotide rests on firmer ground than KPV, with human clinical data against only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on leaky gut and celiac disease has trial data to go on with larazotide; KPV, marketed for inflammation, gut and wound healing, is still an early-research option.
KPV
The anti-inflammatory tail of α-MSH, with real mechanism and real mouse data — but essentially no human trials.
Full KPV evidence reviewLarazotide
AT-1001
A tight-junction regulator with real celiac Phase 2 data — but its pivotal Phase 3 failed, and the supplement use runs far ahead of the evidence.
Full Larazotide evidence reviewKPV vs Larazotide: head to head
- FDA status / approved use
KPV
Unapproved; sold gray-market as a research peptide of unverified contentLarazotide
Investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022- Marketed for
KPV
Inflammation, gut, wound healingLarazotide
Leaky gut, celiac disease- Outcome areas
KPV
Immune function / inflammation; Gut health; Injury recovery / tissue repairLarazotide
Gut health- Evidence grade
KPV
Preclinical / minimalLarazotide
Clinical data- How it works
KPV
Enters cells via the PepT1 transporter and dampens inflammatory NF-κB signalingLarazotide
Zonulin antagonist designed to tighten the junctions between intestinal cells- Route and dosing
KPV
Oral, topical or injectable products; no established doseLarazotide
Oral capsule swallowed before meals- Headline human result
KPV
Not establishedLarazotide
Phase 3 CeDLara trial stopped in 2022 after interim analysis showed it would miss its symptom endpoint- Strongest evidence
KPV
Dalmasso, Gastroenterology 2008. Little or no controlled human outcome data for the marketed useKPV evidence reviewPubMed 18061177Larazotide
Leffler, Gastroenterology 2015Larazotide evidence reviewPubMed 25683116- Key safety signal
KPV
No human safety profile or established dose; products of unverified contentLarazotide
Gray-market products carry contamination, mislabeling and mis-dosing risks- How it is obtained
KPV
Sold gray-market as a research chemical; no approved or legitimately compounded human productLarazotide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals
| KPV | Larazotide | |
|---|---|---|
| FDA status / approved use | Unapproved; sold gray-market as a research peptide of unverified content | Investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022 |
| Marketed for | Inflammation, gut, wound healing | Leaky gut, celiac disease |
| Outcome areas | Immune function / inflammation; Gut health; Injury recovery / tissue repair | Gut health |
| Evidence grade | Preclinical / minimal | Clinical data |
| How it works | Enters cells via the PepT1 transporter and dampens inflammatory NF-κB signaling | Zonulin antagonist designed to tighten the junctions between intestinal cells |
| Route and dosing | Oral, topical or injectable products; no established dose | Oral capsule swallowed before meals |
| Headline human result | Not established | Phase 3 CeDLara trial stopped in 2022 after interim analysis showed it would miss its symptom endpoint |
| Strongest evidence | Dalmasso, Gastroenterology 2008. Little or no controlled human outcome data for the marketed useKPV evidence reviewPubMed 18061177 | Leffler, Gastroenterology 2015Larazotide evidence reviewPubMed 25683116 |
| Key safety signal | No human safety profile or established dose; products of unverified content | Gray-market products carry contamination, mislabeling and mis-dosing risks |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
KPV is preclinical, with a specific PepT1 and NF-kB mechanism and reproducible mouse colitis data, and essentially no human trials. Larazotide is the more advanced molecule and the more instructive failure: its Phase 2b CeliAction trial found the 0.5 mg dose reduced symptoms versus placebo, but the pivotal Phase 3 CeDLara trial was stopped in 2022 after an interim analysis showed it would not meet its primary symptom endpoint. Larazotide is investigational and not FDA-approved for anything, and what evidence it has lives inside diagnosed celiac disease, not general 'leaky gut'. Neither is a demonstrated treatment for intestinal permeability; one has no human data, and the other has human data that came out negative.
KPV fits if
KPV suits the reader who wants to follow an early anti-inflammatory gut mechanism and accepts that the evidence stops at mice.
Larazotide fits if
Larazotide is the more relevant read for anyone specifically interested in celiac disease and tight-junction biology, and for seeing why a failed Phase 3 outweighs a supplement label.
KPV vs Larazotide: common questions
- Is either KPV or larazotide FDA-approved?
- No. KPV is unapproved; sold gray-market as a research peptide of unverified content. Larazotide is investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022.
- Which has stronger human evidence, KPV or larazotide?
- Larazotide. It has human clinical data (key source: Leffler, Gastroenterology 2015), while KPV has only preclinical or minimal evidence (key source: Dalmasso, Gastroenterology 2008).
- What are the main safety concerns with KPV and larazotide?
- KPV has no human safety profile or established dose; products of unverified content. With larazotide, gray-market products carry contamination, mislabeling and mis-dosing risks.
Key studies behind each
KPV
- Luger TA, Brzoska T. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. PubMed 17934097
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177
- Kelly JM, Moir AJ, Carlson K, et al. (2006). Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. PubMed 16274845
- Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346
Larazotide
- Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. (2007). The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. PubMed 17697209
- Fasano A. (2011). Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. PubMed 21248165
- Kelly CP, Green PH, Murray JA, et al. (2013). Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. PubMed 23163616
- Leffler DA, Kelly CP, Green PH, et al. (2015). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. PubMed 25683116
The full evidence reviews
- KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)
KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.
Updated August 2026
- Larazotide: the leaky-gut peptide that failed its Phase 3 trial
An 8-amino-acid tight-junction regulator with real celiac data and a failed pivotal trial — and why the supplement use runs far ahead of the evidence.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm KPV availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: YourHealthRxPeptiYucca HealthRxSpan MDTelos RXDefy Medical